tirzepatide dementia study Tirzepatide: a novel therapeutic approach for Alzheimer's disease GLP-1s May Stave Off Dementia,

Improved metabolic markers Tirzepatide improves blood sugar control, insulin sensitivity, and inflammatory markers

But semaglutide is not the only game in town anymore

A 2022 clinical trial found semaglutide users lost an average of 15 pounds over 68 weeks, compared to 2-3 pounds in metformin-only groups

The goal is to keep the injection pens at a cool and consistent temperature

In this review article, we aimed to update the understanding of the possible roles of HDACs in the pathophysiology of epilepsy, discuss the likely regulatory mechanisms of these enzymes and summarize the recent progress in the development of HDACi in epilepsy rodent models and patients